Health-related quality-of-life results from SANET-ep: A phase III study of surufatinib versus placebo for advanced extrapancreatic neuroendocrine tumors.

Chunmei Bai(Shanxi Medical University), Weiguo Su(Tamedia (Switzerland)), Ying Yuan(Zhejiang Cancer Hospital), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Songhua Fan, Lin Shen(Peking University), Yihebali Chi(Chinese Academy of Medical Sciences & Peking Union Medical College), Yuxian Bai(Harbin Medical University), Mengye Peng, Jing Li(Kunming University of Science and Technology), Jia Chen(Heilongjiang University of Chinese Medicine), Jie Li(Nanjing University of Chinese Medicine), Zhiping Li(Sichuan University), Tianshu Liu(Sun Yat-sen University), Xiuwen Wang(Second Hospital of Shandong University), Xingya Li(Zhengzhou University), Jianming Xu(81th Hospital of PLA), Enxiao Li(First Affiliated Hospital of Xi'an Jiaotong University), Nong Xu(First Affiliated Hospital Zhejiang University), Zhiwei Zhou(Sun Yat-sen University)
Journal of Clinical Oncology
May 20, 2020
10.1200/jco.2020.38.15_suppl.4613
Cited by 1

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2023|1.1k
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
|Nature|2021|687